Cynthia Butitta (L) and Joe Jimenez

Is that an­oth­er IPO in the mak­ing? Ex-No­var­tis CEO Joe Jimenez and a lead Kite play­er take up new posts at an off-the-shelf ri­val to 2 pi­o­neer­ing drugs

Right on the heels of tak­ing on a $160 mil­lion crossover round in a like­ly leap to Nas­daq, Cen­tu­ry Ther­a­peu­tics CEO La­lo Flo­res is now push­ing ahead with the high-pro­file ex-No­var­tis chief Joe Jimenez as chair­man.

Jimenez’s great­est fame at No­var­tis was earned for one of its weak­est prod­ucts, as their pi­o­neer­ing per­son­al­ized CAR-T Kym­ri­ah won the hon­ors for the first such drug to make it to the mar­ket. Now a host of play­ers, in­clud­ing Cen­tu­ry, are bar­rel­ing in be­hind the fron­trun­ners with al­lo­gene­ic ri­vals that can be cre­at­ed for off-the-shelf use.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.